or any other medication described. The comparisons include any of the medications described as an intervention, compared in a head-to-head fashion or compared with placebo or no treatment. The outcomes include clinical response, histological response, quality of life, and adverse events according to the outcome description in the included studies.
Question 3. In patients successfully treated for MC (either LC or CC) and in remission of symptoms, which treatments are effective and safe for maintaining clinical remission of the disease, measured as maintenance of clinical response, maintenance of histological response, time to relapse, quality of life, and adverse events?
The population is adult patients successfully treated for MC (either LC or CC) and in remission of symptoms. The interventions include budesonide, a thiopurine agent (azathioprine), or any other intervention described in the literature for maintaining remission of MC. The comparisons include head-tohead comparisons among any of the interventions identified, placebo, or no treatment. The outcomes include maintenance of clinical response, maintenance of histological response, time to relapse, quality of life, and adverse events, as described in the included studies.
A summary of the focused questions and PICO components is shown in Table 1 .
Definition of the Relative Importance of Outcomes
After defining the included outcomes for each focused question, an online survey was circulated among panel members participating in this review. In this survey, participants were asked to rank the outcomes according to their relative importance. The process was conducted individually and independently. In the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, the relative importance of an outcome is defined on a scale from 1 (least important) to 9 (most critical); those rated from 1 to 3 are defined as of limited importance, from 4 to 6 as important, and from 7 to 9 as critical. 2 The panel was not aware of the quality of the evidence for each of the outcomes at the moment of assessing their importance. The results of the determination of the relative importance of the outcomes are shown in Table 2 .
Study Selection Criteria and Search Strategy per Question
Question 1. What is the prevalence of MC? How many colon biopsy specimens should be obtained and from which areas of the colon?
Study selection criteria. We included studies recruiting patients with both LC and CC. For estimation of the prevalence of the disease, we selected studies based on populations of patients with chronic diarrhea. These studies also provided a description of the diagnostic test used, number of biopsy specimens obtained, and areas of the colon from which biopsy specimens were obtained. We excluded editorial letters, comments, notes, or case reports.
Search strategy and databases. We searched Ovid MEDLINE, Ovid EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), and the Cochrane Database of Systematic Reviews from inception to August 2014. The search strategy included terms such as "microscopic colitis," "colonoscopy," and "biopsy," among others. There was no restriction by language or status of publication. For more details about the search strategy, see Appendix 1.
Question 2. In patients with MC (either LC or CC), which treatments are effective and safe for inducing remission of the disease, measured as clinical response, histological response, quality of life, and adverse events?
Study selection criteria. We included studies that recruited participants with a confirmed diagnosis of MC, irrespective of whether the patients had CC or LC. In addition, the studies provided information about the effectiveness and safety profile of any medication to treat these conditions compared with other interventions in a head-to-head comparison or placebo. For this question, we excluded studies reporting on the effect of interventions for maintaining remission of MC, because these studies are covered in question 3. Given that we were anticipating scarce evidence to answer this question, we included both randomized controlled trials and observational studies during the initial screening process. Good-quality observational studies were included in the review along with the controlled trials.
Search strategy and databases. We searched Ovid MEDLINE from 1946 to July week 4 2014, Ovid EMBASE from 1980 to 2014 week 31, the Cochrane Central Register of Controlled Trials (CENTRAL) to June 2014, and the Cochrane Database of Systematic Reviews from 2005 to June 2014. The search strategy included terms describing the disease and all medications available for inducing remission of MC. There was no restriction by language. We excluded editorial letters, comments, notes, or case reports. For more details about the search strategy, see Appendix 2.
Study selection criteria. We included treatment trials for patients with a confirmed diagnosis of MC, including both CC and LC, who were in clinical remission. Studies were selected that included information about the effectiveness and safety profile of any medication to maintain remission. We included interventions for maintaining remission compared with other 
Study Selection Process
After removing duplicates, 2 researchers independently assessed the retrieved references for eligibility using the title and abstract. References that showed potential eligibility were assessed again in duplicate and independently, this time using full text. A piloted form including the main eligibility criteria helped to document this process. When there was disagreement, a third person arbitrated to make the final inclusion decision.
Data Extraction and Analysis
Using a piloted form, data extraction was conducted by one researcher and a second reviewer checked for accuracy. The information retrieved from primary studies included their main features, type of design, patient characteristics, clinical and histological definition of MC, risk of bias assessment, and outcomes measured.
When feasible, contingency tables were created for each dichotomous outcome, and the relative risk (RR) and its 95% confidence interval (CI) was calculated. When data from intention-to-treat analysis were shown, this was preferred over per-protocol analysis. The only exception to this was the outcome of adverse events, for which per-protocol analysis was performed. For continuous outcomes, the mean difference (MD) and its 95% CI was calculated. To facilitate decision making, the data from studies reporting clinical relapse during the maintenance period were transformed from the number of patients free from relapse to the number of participants having the event. When aggregated data such as standard deviation for a group were missing, the exact P value was used to approximate it. A random effects model was chosen a priori given that different dosages and methods of administration of medications were expected, representing a distribution of results of effectiveness. Review Manager 5.3 software (Nordic Cochrane Centre, Cochrane Collaboration, Copenhagen, Denmark) was use to conduct the meta-analyses.
Risk of Bias Assessment of Included Studies
To determine the risk of bias of included studies, the Cochrane Risk of Bias Tool for randomized controlled trials 3 and diagnostic test accuracy studies 4 were used. For randomized controlled trials, the following domains were considered: (1) Was the random sequence adequately generated? (2) Was the allocation adequately concealed? (3) Were participants blinded to the intervention received? (4) Were personnel blinded to the intervention administered? (5) Were outcome adjudicators blinded to the intervention administered? (6) Was the study affected by incomplete outcome data? (7) Was the study affected by selective outcome reporting? (8) Was any other additional bias identified? The domains considered to assess the risk of bias of diagnostic test accuracy were as follows: (1) Was the spectrum of patients representative of the patients who will receive the test in practice? (2) Is the reference standard likely to classify the target condition correctly? (3) Is the time period between the reference standard and the index test short enough to be reasonably sure that the target condition did not change between the 2 tests? (4) Did the whole sample, or a random selection of the sample, receive verification using the intended reference standard? (5) Did patients 
Evaluation of the Quality of the Body of Evidence
The quality of the body of evidence (also known as confidence or certainty in the evidence) across outcomes was assessed using the GRADE approach. 2 In this approach, randomized controlled trials start as high-quality evidence; however, the confidence in the estimates of effect can be downgraded from high to moderate, low, or very low when serious or very serious issues related to risk of bias, imprecision, indirectness, inconsistency, and publication bias are identified. For diagnostic test accuracy studies using a crosssectional design, the quality of the evidence starts as high and the same domains were assessed to determine whether downgrading was necessary. 5 Results were tabulated using evidence profiles and evidence to decision tables. The Guideline Development Tool (GDT) software was used to assess and record judgments related to the quality of evidence assessment and move from the evidence to decisions (www. guidelinedevelopment.org).
Results

Systematic Search Retrieval and Study Selection
The search strategy retrieved 1239 articles, of which 402 were duplicates. The remaining 837 references went to the title and abstract screening stage. Then, 51 were included for full-text screening. A total of 29 primary studies proved eligible (Figure 1 ). Question 2. In patients with MC (either LC or CC), which treatments are effective and safe for inducing remission of the disease, measured as clinical response, histological response, quality of life, and adverse events?
The search strategy retrieved 592 articles, of which 162 were duplicates. The remaining 430 references went to the title and abstract screening stage. Then, 76 were included for full-text screening. A total of 12 primary studies proved eligible (Figure 2 ). Question 3. In patients successfully treated for MC (either LC or CC) and in remission of symptoms, which treatments are effective and safe for maintaining clinical remission of the disease, measured as maintenance of clinical response, maintenance of histological response, time to relapse, quality of life, and adverse events?
The search strategy retrieved 592 articles, of which 162 were duplicates. The remaining 430 references went to the title and abstract screening stage. Then, 80 were included for full-text screening. A total of 3 primary studies proved eligible ( Figure 3 ).
Description of Included Studies
Studies included in question 1. The purpose of this question was to inform clinicians about the prevalence of the disease and the number of biopsy specimens that should be taken along with the areas from the colon that need to be considered. This question was not framed as a PICO question linked to a recommendation because this was classified as a background question. Its content is included in the guideline (these studies are not included in the current review).
Studies included in questions 2 and 3. Table 3 shows a detailed description of the included studies. These studies were published between 1999 and 2014 and conducted in Belgium, Germany, Denmark, Lithuania, and Italy. The proportion of female participants ranged from 67% to 93%. The mode for the age was 60 years. Follow-up ranged from 2 to 25 weeks. For more details about these studies and their characteristics, interventions, and comparisons, see Table 3 .
Risk of Bias Assessment of Included Studies
Randomized controlled trials. Of the 15 included randomized controlled trials, 7 were assessed as unclear for the domain related to the way the random sequence generation was created. [6] [7] [8] [9] [10] [11] [12] In the allocation concealment domain, 10 of 15 trials were assessed as unclear risk of bias due to limited information regarding the methods used to protect the sequence at the moment of randomization. The domain that had the highest risk of bias classification was the one asking whether selective outcome reporting was present. 6, [8] [9] [10] [11] [12] [13] [14] Frequently, the investigators did not provide numerical data for outcomes when the study failed to show statistical significance and did not report measures of variability for continuous outcomes; some of the investigators did not report relevant outcomes such as histological response and quality of life. Three trials showed low risk of bias overall [15] [16] [17] ( Figure 4 ). Bismuth subsalicylate versus no treatment for inducing remission. Only one randomized controlled trial reported results comparing bismuth subsalicylate (eight 262-mg chewable tablets [Pepto-Bismol; Procter & Gamble, Cincinnati, OH] per day for 8 weeks in 3 doses: 3 tablets in the morning, 2 at midday, and 3 in the evening) with placebo (Table 4) . 18 This small trial included 14 participants and has only been published as an abstract. Because there were no events in the control arm for the clinical response and adverse events outcomes, it was not possible to calculate absolute and relative estimates. 19 There was a 206% increase in the histological response of participants receiving the intervention after 8 weeks of follow-up; however, this difference was not statistically significant (RR, 3.06; 95% CI, 0.3-30.97). No participants experienced adverse events. Quality of life was not measured in the context of this study. The quality of the evidence for all reported outcomes was low due to very serious imprecision.
Effect of the Interventions and Assessment of the Quality of the Evidence
Prednisolone versus no treatment for inducing remission of MC. Only one trial reported data comparing the effect of prednisolone (50 mg once daily for 2 weeks and then 37.5 mg for 1 week) with placebo (Table 5) . 11 This small trial included 12 participants. Because there were no events in the control arm for the outcome of clinical response, it was not possible to calculate absolute and relative estimates. 19 The quality of evidence for this outcome was assessed as very low due to serious issues of risk of bias and very serious issues of imprecision. Adverse events associated with the intervention included the typical adverse effects related to the use of a corticosteroid and were not severe enough to cause participants to withdraw from the study. The quality of the evidence for this outcome was low due to serious issues of risk of bias and imprecision. Histological response and quality of life were not reported in this trial.
Budesonide versus no treatment for inducing remission of MC. The effect of budesonide (9 mg once daily [three 3-mg capsules]) was based on 6 studies and one additional report published separately (Table 6) . 6, 7, 12, [15] [16] [17] 20 In total, 218 participants informed the outcome of clinical 6, 7, [15] [16] [17] Patients receiving budesonide were 150% more likely to have histological remission after 6 to 8 weeks of follow-up (RR, 2.5; 95% CI, 1.56-3.99). In absolute terms, 421 more patients per 1000 would experience this outcome. The quality of the evidence for this outcome was determined to be moderate due to serious issues of inconsistency. Two studies informed about the time to induce clinical remission. 15, 17 Given that the authors of one of the studies did not provide measures of variability, a meta-analysis was not possible. Seven to 13 days was the range of estimated mean days to induce clinical remission (range, 2-30 days). This outcome had moderate-quality evidence due to risk of bias. Five studies 6, 12, [15] [16] [17] reported data on adverse events after 6 to 8 weeks of follow-up, but only 3 of them contributed to the metaanalysis. [15] [16] [17] In relative terms, participants receiving budesonide have a 16% increase in the risk of experiencing mild or minor adverse events; however, the difference between groups was not statistically significant (RR, 1.16; 95% CI, 0.45-3). Two additional studies reported adverse events but were not included in this meta-analysis. In 2002, Baert et al 6 reported only minor adverse events related to study medications but did not report them separately for the budesonide and placebo groups (viral 12 (abstract only) stated that no significant adverse effects occurred, but no numerical data were provided. This outcome is informed by low-quality evidence due to serious issues of inconsistency and imprecision. Finally, 2 trials reported data on the effect of budesonide on patients' quality of life. 16, 20 One study showed an increase in quality of life measured with the Gastrointestinal Quality of Life Index (GIQLI) of 23 points, although this increase was not statistically significant (MD, 23; 95% CI, À7.49 to 53.5). One additional study reported quality of life using the SF-36 instrument. In 2009, Miehlke et al 16 reported an increase in the mean change in the physical sum score of 3.5 points and in the mental sum score of 3.1 points. Serious issues of imprecision warrant a determination of moderate-quality evidence for this outcome. Interaction testing showed no difference in treatment response or other outcomes when comparing patients with CC or LC.
Budesonide versus mesalamine for inducing remission of MC. One trial provided evidence of the effect of budesonide (9 mg once daily [three 3-mg capsules]) compared with mesalamine (3 g once daily [2 sachets each containing 1.5 g mesalamine presented as a granule formulation; Salofalk; Dr. Falk Pharma, Freiburg, Germany]) ( Table 7) . 17 Only 55 patients informed the outcome of clinical remission. Those receiving budesonide had an 82% increase in the probability of experiencing the outcome (RR, 1.82; 95% CI, 1.13-2.93) compared with those receiving mesalamine. This finding is supported by high-quality evidence. For the outcome of histological response, patients receiving budesonide showed a 96% increase in the probability of experiencing the outcome (RR, 1.96; 95% CI, 1.14-3.36), which in relative terms corresponds to 427 more people per 1000 experiencing the benefit. This finding is supported by high-quality evidence. Regarding adverse events, patients receiving budesonide had a lower risk of experiencing these compared with those receiving mesalamine; however, this difference was not statistically significant (RR, 0.69; 95% CI, 0.43-1.1). This finding is supported by moderate-quality evidence due to serious issues of imprecision. Quality of life was not reported. Interaction testing showed no difference in treatment response or other outcomes when comparing patients with CC or LC.
Mesalamine versus no treatment for inducing remission of MC. One study reported on the effect of mesalamine versus placebo in 62 participants (Table 8) . 17 Patients receiving mesalamine (3 g once daily [2 sachets each containing 1.5 g presented as a granule formulation; Salofalk]) had a lower risk of experiencing clinical remission compared with those receiving placebo after 8 weeks; however, this difference was not statistically significant (RR, 0.74; 95% CI, 0.44-1.24), and it is supported by moderate-quality evidence due to serious imprecision. Regarding histological response, mesalamine seems to reduce the possibility of experiencing histological remission compared with placebo; however, this difference was not statistically significant (RR, 0.89; 95% CI, 0.46-1.73). The quality of the evidence was determined as moderate for this outcome due to serious imprecision. For the outcome of adverse events, 68% of the patients experienced mild or minor adverse events compared with 54% in the control group; however, this difference was not statistically significant (RR, 1.26; 95% CI, 0.84-1.88). This estimate is supported by moderate-quality evidence. No evidence for quality of life was reported.
Mesalazine plus cholestyramine versus mesalazine for inducing remission of MC. One trial reported evidence on the effect of cholestyramine in addition to mesalazine (mesalazine 800 mg, one capsule after breakfast, lunch, and dinner [2.4 g daily], and cholestyramine 4 g after dinner for 6 months) compared with mesalazine alone (mesalazine 800 mg, one capsule after breakfast, lunch, and dinner [2.4 g daily]) ( Table 9) . 21 In this trial, which included 64 patients, those receiving mesalazine plus cholestyramine experienced a 9% increased probability of clinical remission when comparing with those receiving mesalazine 
High risk of bias due to selective outcome reporting (no histological response reported) and stopping early due to lack of effectiveness. It is unclear how the randomization scheme was created and the allocation sequence concealed. The study included only 2 events, with zero events in the control group, which prevents estimation of absolute effect. Given that there were no events in the control group, the RR and absolute risk reduction could not be estimated. c The study included only 12 participants; 9 received prednisolone. 12 (2009, abstract) only describe that no significant side effects occurred; no numerical data were provided. e The most common adverse events listed in the studies were nausea, headache, abdominal pain, and skin rash. f Unexplained heterogeneity among included studies (c 2 P value ¼ .08; I 2 ¼ 60%). g The lower and upper boundaries of the CI suggest both large benefit and harm. h The GIQLI score consists of 4 dimensions (symptoms, physical functioning, emotional functioning, and social functioning). The overall score ranges from 0 to 144 (the higher the score, the better the quality of life). Healthy volunteers have been reported to have a mean score of 121-126 using the GIQLI. These values compare with previously reported mean scores of 104 in patients with anal fissures, 94 in those with severe chronic constipation, 93 in those with fecal incontinence, and 87 in those with gastroesophageal reflux disease requiring surgery. 29 i One additional study reported quality of life using the SF-36 instrument. Miehlke et al 16 (2009) reported an increase in the mean of the change for the physical sum score of 3.5 points and for the mental sum score of 3.1 points. j There was a large difference in baseline quality of life between patients in the budesonide arm (67 points) and those in the control group (86 points). k The lower and upper boundaries of the CI suggest small harm and large benefit. None of the outcomes show statistically significant differences between the 2 groups. In addition, the quality of evidence was assessed as low for all outcomes due to serious imprecision. The outcome of quality of life was not reported for this comparison. There are no clinical trials assessing the efficacy of cholestyramine or other bile acid-binding medication alone. Boswellia serrata versus treatment for inducing remission of MC. One trial reported data on 31 patients for the effect of B serrata, 400 mg per capsule 3 times per day (21.2 mg 11-keto-b-boswellia acid, 27.3 mg a-boswellia acid, 50.9 mg b-boswellia acid, 11.3 mg acetyl-11-keto-bboswellia acid, 9.8 mg acetyl-a-boswellia acid, and 28.7 mg acetyl-b-boswellia acid), versus placebo (Table 10 ).
14 Participants receiving B serrata showed a 64% increase in the probability of experiencing a clinical response after 6 weeks (RR, 1.64; 95% CI, 0.60-4.49); however, this difference was not statistically significant. This finding is supported by moderate-quality evidence due to serious imprecision. For the outcome of histological response, the investigators only declared that there was no statistically significant difference between groups, supported by moderate-quality evidence due to serious risk of bias. Participants receiving B serrata experienced more adverse events compared with those in the placebo group; however, this difference was not statistically significant (RR, 1.88; 95% CI, 0.19-18.6). Low confidence in the estimates of effect was determined for this outcome due to very serious issues of imprecision. Finally, the investigators reported that at the end of 6 weeks of therapy, there were no significant changes in quality of life scores in the B serrata or placebo groups when comparing baseline with posttreatment or between groups after treatment was completed. No numerical data were provided for this outcome. Serious risk of bias due to selective outcome reporting led to a determination of moderatequality evidence.
Probiotics versus no treatment for inducing remission of MC. One trial, which included 29 participants, informed about the effect of a probiotic (AB-Cap-10, a mixture of Lactobacillus acidophilus strain LA-5 and Bifidobacterium animalis subsp lactis strain BB-12) compared with placebo for inducing remission of MC (Table 11) . 13 The use of the probiotic increased the probability of experiencing clinical remission after 12 weeks by 129% (RR, 2.29; 95% CI, 0.32-16.13); however, this difference was not statistically significant. These findings are supported by moderatequality evidence. Regarding histological response, no numerical data were reported, but the investigators declared "no differences in histopathological changes between or within groups were observed after 12 weeks." This finding is supported by low-quality evidence. For the outcome of adverse events, the probiotic group experienced worsening of diarrhea, abdominal pain and constipation, stomach burning, nausea, and flatulence after 12 weeks of followup; these findings are supported by moderate-quality evidence. Finally, quality of life was assessed using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ) after 12 weeks. An increase in the instrument score of 3% (no information on variability for this estimate was reported) was observed. This finding is supported by low-quality evidence.
Beclomethasone versus mesalazine for inducing remission of MC. One trial, which included 33 participants, reported data for this comparison. 8 Two doses of beclomethasone dipropionate, 5 mg/day and 10 mg/day, were compared with mesalazine 2.4 mg/day. Although the interaction test showed no statistically significant differences between the 2 doses, the results are reported separately for convenience. For both doses, beclomethasone showed a reduction in the probability of experiencing clinical remission of 4% for the 5-mg dose and 2% for the 10-mg dose when compared with mesalazine after 8 weeks. Regarding the outcome of adverse events, the authors only reported that beclomethasone and mesalazine were well tolerated with no serious side effects (no numerical data were provided). Low confidence in estimates of effect was determined for all these outcomes due to serious imprecision and very serious risk of bias. Neither histological response nor quality of life were reported (Table 12 ). Question 3. In patients successfully treated for MC (either LC or CC) and in remission of symptoms, which treatments are effective and safe for maintaining clinical remission of the disease, measured as maintenance of clinical response, maintenance of histological response, time to relapse, quality of life, and adverse events?
Budesonide versus no treatment for maintaining remission of MC. Three randomized controlled trials, including a total of 80 participants, reported data for this comparison (Table 13) . 9, 10, 22 Two doses of budesonide were studied to maintain clinical remission: 6 mg once a day (two 3-mg capsules for 6 months) 9,22 and 4.5 mg/day (two 3-mg capsules every other day alternating with one 3-mg capsule every other day for 12 months). 10 The 6-mg dose reduced the risk of clinical relapse at 6 months by 66% (RR, 0.34; 95% CI, 0.19-0.6), which in absolute terms means that 495 relapse events can be avoided per 1000 people. This finding is supported by high-quality evidence. The 4.5-mg dose also showed a reduction in the risk of experiencing a relapse of 54% (RR, 0.46; 95% CI, 0.31-0.69) compared with placebo after 13 months of 10 (2014) , not included in the meta-analysis, reported a mean of 40 days to relapse after maintenance therapy (range, 27-57 days). d Unexplained heterogeneity between the 2 studies reporting this outcome. Results differ considerably. e Among budesonide recipients, Miehlke et al 9 (2008) reported adverse events, including headache (2), urinary infection (1), respiratory infection (1), back pain (1), abdominal pain (1), increased body weight (1), and hypertension (1). Among patients who withdrew from the study, adverse events included dizziness (1), sleep disturbance (1), muscle pain (1), gastric ulcer (1), and skin erythema (1). Bonderup et al 22 (2009) reported worsening of diabetes (2), dyspepsia (1), bruising (1), and subarachnoid hemorrhage (1). The latter adverse event, which occurred after 22 weeks of active treatment (ie, 6 weeks of induction plus 16 weeks of maintenance therapy), was considered to be serious and the patient was withdrawn from the study. f Limits of the CI include both appreciable benefit and large harm. g The investigators did not report adverse events in detail (described as an adverse drug reaction). h High risk of bias due to selective outcome reporting. No numerical data were provided.
follow-up. In absolute terms, 450 relapse events can be avoided per 1000 people. The quality of the evidence for this outcome was also assessed as high. Regarding maintenance of histological response, the meta-analysis showed that budesonide 6 mg reduces the risk of histological relapse by 79% (RR, 0.21; 95% CI, 0.08-0.54). In absolute terms, this means that 307 histological relapse events can be avoided per 1000 people. The quality of the evidence for this outcome was also assessed as high. After 6 months of follow-up, the time to relapse during maintenance therapy was on average 161 days longer for the patients in the budesonide group compared with those receiving placebo (MD, 161; 95% CI, 7.8-314.2). This finding is supported by moderate-quality evidence. The time to relapse after maintenance therapy was completed (without medication) was 1 day longer in patients receiving budesonide compared with placebo (MD, 1; 95% CI, À4.1 to 6.1); however, this difference was not statistically significant. The 2014 study by Munch et al, 10 which was included in the meta-analysis, reported a mean of 40 days to relapse after maintenance therapy (range, 27-57 days). This outcome was assessed as having moderate-quality evidence due to serious inconsistency. Adverse events were also analyzed separately for both doses to facilitate decision making. For both the 6-mg and 3-mg doses of budesonide, there were no statistically significant differences between the 2 groups. However, there is no evidence regarding long-term toxicity in patients treated with budesonide for more than 6 months. It has been recommended that these patients be monitored for corticosteroid-related adverse effects. 23 Quality of life was measured in 2 trials. Miehlke et al 9 reported that physical and mental SF-36 scores in patients receiving budesonide increased to levels similar to those observed in "normal" subjects after induction, and these changes remained stable during maintenance therapy. However, no numerical data were reported. Munch et al 10 reported that quality of life did not change after 1 year of treatment with budesonide; however, participants receiving placebo showed a clinically relevant deterioration. No numerical data were provided. The quality of the evidence for this outcome was assessed as moderate due to serious risk of bias issues.
The pooled treatment effects for all outcomes and for all comparisons are presented in Appendix 3.
Discussion
Summary of the Main Results
This review summarizes the best available evidence related to the medical management of MC and clinical features to diagnose celiac disease in this type of patient. A total of 17 primary studies contributed to the body of evidence. The medical interventions identified covered both induction and maintenance of remission of MC. The most promising intervention identified for both purposes was budesonide, supported by moderate-to high-quality evidence. The results for other interventions were too imprecise to draw meaningful conclusions. The selection criteria and outcome definition were consistent across trials. The main risk of bias identified was for the question "Was the study affected by selective outcome reporting?" In this case, 8 of 15 studies were classified as "high risk of bias" due to the fact that the investigators did not provide numerical data for their results but only stated a lack of statistical significance.
Quality of the Evidence
The quality of the evidence ranged from high to very low across outcomes. The main reasons for downgrading were issues of serious imprecision due to the small number of participants per trial and risk of bias mainly due to selective outcome reporting. Investigators tended to avoid reporting numerical data when the trial showed results that were not statistically significant, making it impossible to include these data in the meta-analyses.
Comparison With Previous Systematic Reviews
To our knowledge, this is the most updated systematic review on interventions to treat MC. Previous reviews included fewer studies and had less precise results but came to similar conclusions regarding the role of budesonide as the most studied medication for treating MC. [24] [25] [26] [27] [28] The inclusion of 3 new randomized controlled trials 10, 16, 17 with 218 patients increased the number of participants compared with the previous reviews such that imprecision is no longer an issue for many outcomes. In particular, this review increased the certainty about the role of budesonide for both inducing and maintaining clinical remission.
Strengths and Limitations of This Review
The strengths of this review include the comprehensive search strategy that included multiple databases. In addition, the absence of restriction by language or status of publication allowed us to include key abstracts from conferences and other meetings that have not been published in full version. Screening for articles was conducted independently and in duplicate, while a second reviewer checked the data extraction process. A limitation was that, for many interventions identified, serious imprecision did not allow more definitive conclusions. In general, the trials included few participants and events that affected the precision of the CIs.
Conclusions
Implications for clinical practice. The most important finding of this review for clinical practice is the effectiveness of budesonide and the role of this medication for inducing and maintaining remission of MC.
Implications for research. Multicenter, high-quality, randomized controlled trials of new treatments should be conducted, particularly of noncorticosteroid medications and comparing budesonide with other interventions. More interventions to manage MC should be investigated, particularly to identify effective alternatives to budesonide.
